Halt-It Trial
Start date:August 2014 End date:
November 2016 Co-ordinated by:
London School of Hygiene and Tropical Medicine Main trial site:
http://haltit.lshtm.ac.uk
HALT-IT trial, Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
Aim
The HALT‐IT trial will determine the effect of early administration of TXA on mortality, morbidity (re‐bleeding, non‐fatal vascular events), blood transfusion, surgical intervention and health status in patients with acute gastrointestinal bleeding.
Trial Design
A pragmatic, randomised, double blind, placebo controlled trial among 8,000 patients with significant gastrointestinal bleeding.
Eligibility criteria
Patients with significant GI bleeds in whom the use of tranexamic acid is neither indicated nor contraindicated
Chief Investigator
Professor Iain Roberts (LSHTM)
Local PI
Dr Matt Reed (RIE)
Research Team
Dr Nick Church
Dr James Dear
Dr Kallirroi Kefala
Julia Grahamslaw – local EMeRGE study lead
ED research nurses
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
Research Team
Julia Grahamslaw
Lead Research Nurse
Bernadette Gallagher
Senior Research Nurse
More EMERGE Trials
TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.
TARGET-CTCA Trial
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
IONA Study
Identification of Novel Psychoactive Substances (IONA)
ISARIC4C – Coronavirus Clinical Characterisation Consortium, an observational study
ISARIC/WHO Clinical Characterisation Protocol for Severe Emerging Infections in the UK (CCP-UK)